SEC Form 4 · accession 0001179110-18-005443
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stan Bukofzer
Officer — Chief Medical Officer & SVP***
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 8:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Apr 2, 2018 | A | 91,324 | A | — | — | Common Stock | 91,324 | 91,324 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- F2These Restricted Stock Units are scheduled to vest 27.78% on April 2, 2019, 27.78% on April 2, 2020 and 44.44% on April 2021 assuming continued employment through the applicable vesting date.
Remarks
*** Stanley's title is Chief Medical and Scientific Officer, Senior Vice President.